Plaquenil is not an NSAID. It belongs to a completely different class of medication called antimalarials, and it is also classified as a disease-modifying antirheumatic drug (DMARD). While NSAIDs like ibuprofen and naproxen reduce pain and inflammation quickly, Plaquenil works on a deeper level by modifying how the immune system behaves. The distinction matters because these two drug classes do fundamentally different things in your body.
How Plaquenil Is Classified
Hydroxychloroquine, sold under the brand name Plaquenil, was originally developed to treat malaria. It is now FDA-approved for two autoimmune conditions: lupus (both the skin-limited and systemic forms) and rheumatoid arthritis in adults. The Hospital for Special Surgery lists it alongside methotrexate, sulfasalazine, leflunomide, and azathioprine as a traditional DMARD.
NSAIDs, by contrast, are a broad category of pain relievers that includes over-the-counter drugs like ibuprofen (Advil), naproxen (Aleve), and aspirin. They are designed to reduce pain, swelling, and fever, but they don’t change the underlying course of a disease. Plaquenil does.
Why the Mechanism Matters
NSAIDs work by blocking enzymes called COX-1 and COX-2, which your body uses to produce chemicals that trigger pain and inflammation. This is why they provide fast, noticeable relief, often within an hour or two of taking a dose. But once the drug wears off, the underlying disease process continues unchecked.
Plaquenil operates through an entirely different pathway. It suppresses the activation of sensors on immune cells called Toll-like receptors, which play a central role in the body’s inflammatory and autoimmune responses. When these receptors fire in someone with lupus or rheumatoid arthritis, they trigger the production of signaling molecules that drive chronic inflammation. Plaquenil binds to nucleic acids in this activation pathway, essentially preventing those receptors from sounding the alarm. The result is a dampened, better-regulated immune response rather than just temporary pain relief.
This is why Plaquenil takes so much longer to work. Symptoms may start improving in one to two months, but it can take up to six months to feel the full benefit. NSAIDs work the same day you take them. That difference in speed reflects the difference in what each drug is actually doing: one is masking symptoms, the other is reining in the disease itself.
Disease Modification vs. Symptom Relief
The most important practical difference between Plaquenil and NSAIDs is what happens to your joints and organs over time. DMARDs like Plaquenil don’t just control inflammation. They actually prevent the long-term damage that autoimmune diseases cause, including joint erosion in rheumatoid arthritis and organ involvement in lupus. NSAIDs do neither. They manage how you feel on a given day, but they cannot slow or stop disease progression.
This is also why the two are often used together. NSAIDs are generally safe to take alongside DMARDs, providing more immediate pain relief while the slower-acting medication does its work in the background. Many people with rheumatoid arthritis or lupus take both, especially early in treatment before Plaquenil has fully kicked in.
Different Side Effects, Different Monitoring
Because Plaquenil and NSAIDs affect the body through different mechanisms, their risk profiles look nothing alike. The most well-known concern with long-term NSAID use is stomach irritation, ulcers, and an increased risk of heart problems. With Plaquenil, the primary long-term concern is potential damage to the retina.
The American Academy of Ophthalmology recommends a full baseline eye exam, including specialized imaging, soon after starting Plaquenil. Annual eye screening is advised while taking the drug, though it can be deferred during the first five years if no major risk factors are present. Risk factors that call for earlier screening include kidney disease, use of the breast cancer drug tamoxifen, and starting the medication later in life. The recommended dose is kept at or below 5 mg per kilogram of real body weight per day to minimize toxicity risk, and shorter or lighter individuals may need a lower dose than the standard 400 mg daily.
NSAIDs require no routine eye exams. Plaquenil requires no routine stomach monitoring. The side effect profiles simply don’t overlap in meaningful ways, which is another clear signal that these are very different medications.
When Plaquenil Might Be Confused With an NSAID
The confusion likely comes from the fact that both Plaquenil and NSAIDs are prescribed for conditions involving inflammation and joint pain. If your doctor prescribes Plaquenil for rheumatoid arthritis, it’s easy to assume it’s just another anti-inflammatory pill. But the intent behind the prescription is different. Your doctor is not giving you Plaquenil to feel better tomorrow. They’re giving it to change the trajectory of your disease over months and years.
Another source of confusion is that Plaquenil does reduce inflammation, just not through the same mechanism or on the same timeline as NSAIDs. It calms the overactive immune signaling that causes inflammation in the first place, rather than blocking the pain and swelling chemicals that result from it. Think of it this way: NSAIDs mop up the flood, while Plaquenil turns down the faucet.